Hvis transaminaseniveauerne viser tegn på progression, specielt hvis de stiger til 3 x ULN og er vedvarende, bør behandlingen afbrydes.
Patients titrated to the 80-mg dose should receive an additional test prior to titration, 3 months after titration to the 80-mg dose, and periodically thereafter (e. g., semi-annually) for the first year of treatment.